BNP Paribas Financial Markets
ZVRA icon

BNP Paribas Financial Markets’s Zevra Therapeutics ZVRA Stock Holding History

BNP Paribas Financial Markets’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$146K Sell
10,163
-2,701
-21% -$30K ﹤0.01% 4363
2026
Q1 		$120K Sell
12,864
-68
-0.5% -$613 ﹤0.01% 4284
2025
Q4 		$116K Buy
12,932
+1,939
+18% +$18.3K ﹤0.01% 4316
2025
Q3 		$105K Sell
10,993
-31,957
-74% -$320K ﹤0.01% 4274
2025
Q2 		$378K Buy
42,950
+39,746
+1,241% +$323K ﹤0.01% 3493
2025
Q1 		$24K Sell
3,204
-3,142
-50% -$25K ﹤0.01% 4487
2024
Q4 		$52.9K Buy
+6,346
New +$54.2K ﹤0.01% 4408

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

BNP Paribas Financial Markets's ZVRA Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its Zevra Therapeutics (ZVRA) stake by 21% in Q2 2026, selling an estimated $30K and leaving 10,163 shares worth $146K. The position accounts for ﹤0.01% of the portfolio, ranked #4363.

BNP Paribas Financial Markets first reported a position in ZVRA in Q4 2024 and has held it in 7 quarters since. The position peaked at $378K in Q2 2025. 144 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • BNP Paribas Financial Markets held 10,163 shares of Zevra Therapeutics worth $146K as of Q2 2026.
  • BNP Paribas Financial Markets sold 2,701 Zevra Therapeutics shares in Q2 2026, an estimated $30K.
  • Zevra Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #4363 holding.
  • BNP Paribas Financial Markets first reported a position in Zevra Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • BNP Paribas Financial Markets's Zevra Therapeutics position peaked at $378K in Q2 2025.
  • 144 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.